Navigation Links
Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
Date:6/4/2010

MALVERN, Pa., June 4 /PRNewswire/ -- Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY) covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death).  These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.

Under the terms of the agreement, Ascenta Therapeutics has given sanofi-aventis an exclusive worldwide license to develop, manufacture, and commercialize all compounds issued from this program. In return, Ascenta will receive an upfront payment, as well as development, regulatory and commercial milestone payments that could reach a total of $398 million. In addition, Ascenta is eligible to receive tiered royalties on worldwide product sales.

The agreement includes two agents that Ascenta Therapeutics previously in-licensed from the University of Michigan, MI-773 and MI-519-64, which should soon enter preclinical development.  Both Ascenta Therapeutics and sanofi-aventis will continue to fund research on these targets at the University of Michigan, and Ascenta Therapeutics may participate in ongoing research activities and potential future clinical development.

"Ascenta's mission since its founding has been to discover and develop novel small molecules that can trigger apoptosis in cancer cells. Sanofi-aventis has a great record of bringing innovati
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
2. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
3. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
6. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
7. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
8. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
9. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
11. Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
(Date:8/27/2014)... MADISON, N.J. , Aug. 27, 2014 /PRNewswire/ ... significant potential to help physicians better identify early-stage ... progression and disability, according to a new study ... from Quest Diagnostics (NYSE: DGX ) ... of the 14-3-3eta protein outperformed conventional antibody-serum testing, ...
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Flagship Biosciences Announces Relocation and Expansion 2
... Pipeline Efforts at 27th Annual J.P. Morgan Healthcare Conference ... (Nasdaq: GHDX ) announced today that it ... 18-gene Oncotype DX(R) colon cancer assay. Utilizing more ... the validation study will use prospectively defined endpoints to ...
... Jan. 12 WaferGen Biosystems,Inc. (OTC Bulletin ... gene,expression, genotyping, cell biology and stem cell ... successfully demonstrated the,performance of the company,s SmartChip(TM) ... the platform,s ongoing alpha testing program. ...
... - Trial conducted by Novartis to evaluate safety and ... with ribavirin in patients with genotypes 2 and 3 ... Sciences, Inc. (Nasdaq: HGSI ) today announced ... trial that will evaluate the safety and efficacy of ...
Cached Biology Technology:Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 4Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 5WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5
(Date:8/28/2014)... examples of complex systems. Their infrastructure equipment requires ... cooling, transport to supply fuel, and ICT systems ... network chain is interconnected with a wider network ... of UK-based scientists has studied various aspects of ... been published in EPJ B by Gaihua Fu ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability in ... that occurs when the regions of the brain ... The use of non-invasive functional neuroimaging tools has ... dyslexia. However, most prior work has focused on ... a gap in our understanding of how multiple ...
(Date:8/28/2014)... in German . ... with the help of sophisticated assembly lines. Mobile assembly carriers, ... part of these assembly lines. In the case of a ... stages arranged in a precise spatial and chronological sequence, resulting ... , The creation of such an assembly line at molecular ...
Breaking Biology News(10 mins):Inter-dependent networks stress test 2Dyslexic readers have disrupted network connections in the brain 2Nanoscale assembly line 2Nanoscale assembly line 3
... of breast cancer that has few treatment options; , ... molecules called microRNA can be used to classify this ... new ways to identify the best therapy for individual ... COLUMBUS, Ohio A new, large-scale study ...
... debate over the use of animals in medical research ... viewpoints are becoming more nuanced, and new initiatives are ... report by The Hastings Center, "Animal Research Ethics: Evolving ... new Web site, animalresearch.thehastingscenter.org , a hub of ...
... at sea, a magnetic map is apparently responsible for their ... data collected over 56 years and reported online on February ... "To find their way back home across thousands of ... exists where they first enter the sea as juveniles," said ...
Cached Biology News:Triple-negative breast cancer subtypes identified using microRNA 2Triple-negative breast cancer subtypes identified using microRNA 3Hastings Center resources chart progress in debate over medical research with animals 2Hastings Center resources chart progress in debate over medical research with animals 3Magnetic map guides salmon home 2
... IonQuest will provide great value plus ... detector has very high sensitivities and ... to the standard conductivity detector, the IonQuest ... as electrochemical, refractive index, UV/Visible, WaveQuest UV/Visible ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
Biology Products: